ATE394403T1 - Anti-angiogenetische arzneimittel - Google Patents

Anti-angiogenetische arzneimittel

Info

Publication number: ATE394403T1
Authority: AT; Austria
Prior art keywords: formula; angiogenetic; drugs; angiogenetic drugs; man
Prior art date: 2002-12-24

Application number

AT03786136T

Other languages

English (en)

Inventor

Richard W A Luke

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-24

Filing date

2003-12-19

Publication date

2008-05-15

2003-12-19 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-05-15 Application granted granted Critical

2008-05-15 Publication of ATE394403T1 publication Critical patent/ATE394403T1/de

Links

239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
108010090091 TIE-2 Receptor Proteins 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

AT03786136T 2002-12-24 2003-12-19 Anti-angiogenetische arzneimittel ATE394403T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0230089.5A GB0230089D0 (en)	2002-12-24	2002-12-24	Therapeutic agents

Publications (1)

Publication Number	Publication Date
ATE394403T1 true ATE394403T1 (de)	2008-05-15

Family

ID=9950374

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03786136T ATE394403T1 (de)	2002-12-24	2003-12-19	Anti-angiogenetische arzneimittel

Country Status (16)

Country	Link
US (1)	US20060069109A1 (de)
EP (1)	EP1575963B1 (de)
JP (1)	JP2006515593A (de)
KR (1)	KR20050087852A (de)
CN (1)	CN1751052A (de)
AT (1)	ATE394403T1 (de)
AU (1)	AU2003295135A1 (de)
BR (1)	BR0317708A (de)
CA (1)	CA2508917A1 (de)
DE (1)	DE60320849D1 (de)
ES (1)	ES2305548T3 (de)
GB (1)	GB0230089D0 (de)
MX (1)	MXPA05006921A (de)
NO (1)	NO20052989L (de)
WO (1)	WO2004058776A1 (de)
ZA (1)	ZA200504827B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7776869B2 (en)	2004-10-18	2010-08-17	Amgen Inc.	Heteroaryl-substituted alkyne compounds and method of use
GB0502418D0 (en) *	2005-02-05	2005-03-16	Astrazeneca Ab	Compounds
SI1973545T1 (sl) *	2005-12-23	2013-04-30	Ariad Pharmaceuticals, Inc.	Spojine bicikličnega heteroarila
AU2015210454B2 (en) *	2005-12-23	2016-10-27	Takeda Pharmaceuticals U.S.A., Inc.	Bicyclic heteroaryl compounds
DK1973545T3 (da)	2005-12-23	2013-02-25	Ariad Pharma Inc	Bicykliske heteroarylforbindelser
ES2555515T3 (es)	2006-05-08	2016-01-04	Ariad Pharmaceuticals, Inc.	Compuestos de heteroarilo monocíclico
WO2007133560A2 (en)	2006-05-08	2007-11-22	Ariad Pharmaceuticals, Inc.	Acetylenic heteroaryl compounds
EP2923703B1 (de)	2006-12-15	2018-09-19	NantBio, Inc.	Triazinderivate und deren therapeutische anwendungen
AU2009262199B2 (en)	2008-06-27	2012-08-09	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
CA2743449C (en)	2008-11-12	2016-10-18	Ariad Pharmaceuticals, Inc.	Pyrazinopyrazines and derivatives as kinase inhibitors
CA2765030C (en)	2009-06-09	2015-10-27	California Capital Equity, Llc	Triazine derivatives and their therapeutical applications
CN102573484B (zh)	2009-06-09	2015-07-01	加利福尼亚资本权益有限责任公司	苄基取代的三嗪衍生物及其治疗应用
EP2308866A1 (de)	2009-10-09	2011-04-13	Bayer CropScience AG	Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP2508511A1 (de)	2011-04-07	2012-10-10	Laboratoire Biodim	Inhibitoren der Virenreplikation, Verfahren zu deren Herstellung und deren therapeutische Verwendung
MX2014014308A (es) *	2012-05-30	2015-02-12	Hoffmann La Roche	Pirrolidino heterociclos.
CA2815506C (en)	2012-12-12	2018-12-11	Ariad Pharmaceuticals, Inc.	Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
WO2021032958A1 (en) *	2019-08-16	2021-02-25	Cyclacel Limited	Process for the preparation of a pyrimidino-diazepine derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20020088406A (ko) *	1999-09-17	2002-11-27	애보트 게엠베하 운트 콤파니 카게	치료제로서의 피라졸로피리미딘
US7189745B1 (en) *	1999-11-22	2007-03-13	Smithkline Beecham Corporation	Compounds
WO2002039954A2 (en) *	2000-11-20	2002-05-23	Smithkline Beecham Corporation	Novel compounds
DE60304718T2 (de) *	2002-08-06	2007-04-26	Astrazeneca Ab	Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

2002
- 2002-12-24 GB GBGB0230089.5A patent/GB0230089D0/en not_active Ceased
2003
- 2003-12-19 ES ES03786136T patent/ES2305548T3/es not_active Expired - Lifetime
- 2003-12-19 CA CA002508917A patent/CA2508917A1/en not_active Abandoned
- 2003-12-19 MX MXPA05006921A patent/MXPA05006921A/es unknown
- 2003-12-19 US US10/540,348 patent/US20060069109A1/en not_active Abandoned
- 2003-12-19 EP EP03786136A patent/EP1575963B1/de not_active Expired - Lifetime
- 2003-12-19 BR BR0317708-4A patent/BR0317708A/pt not_active Application Discontinuation
- 2003-12-19 AT AT03786136T patent/ATE394403T1/de not_active IP Right Cessation
- 2003-12-19 JP JP2004563345A patent/JP2006515593A/ja active Pending
- 2003-12-19 AU AU2003295135A patent/AU2003295135A1/en not_active Abandoned
- 2003-12-19 KR KR1020057011870A patent/KR20050087852A/ko not_active Withdrawn
- 2003-12-19 DE DE60320849T patent/DE60320849D1/de not_active Expired - Fee Related
- 2003-12-19 CN CNA2003801098327A patent/CN1751052A/zh active Pending
- 2003-12-19 WO PCT/GB2003/005568 patent/WO2004058776A1/en not_active Ceased
2005
- 2005-06-13 ZA ZA200504827A patent/ZA200504827B/en unknown
- 2005-06-17 NO NO20052989A patent/NO20052989L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004058776A1 (en)	2004-07-15
AU2003295135A1 (en)	2004-07-22
NO20052989D0 (no)	2005-06-17
GB0230089D0 (en)	2003-01-29
EP1575963B1 (de)	2008-05-07
CA2508917A1 (en)	2004-07-15
ES2305548T3 (es)	2008-11-01
CN1751052A (zh)	2006-03-22
MXPA05006921A (es)	2005-08-18
NO20052989L (no)	2005-07-21
US20060069109A1 (en)	2006-03-30
JP2006515593A (ja)	2006-06-01
ZA200504827B (en)	2006-04-26
EP1575963A1 (de)	2005-09-21
DE60320849D1 (de)	2008-06-19
KR20050087852A (ko)	2005-08-31
BR0317708A (pt)	2005-11-22

Legal Events

Date	Code	Title	Description
2008-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60320849D1 (de)	2008-06-19	Anti-angiogenetische arzneimittel
LTC1482932I2 (lt)	2026-04-10	N3 alkilinto benzimidazolo dariniai kaip MEK inhibitoriai
CY1115925T1 (el)	2017-01-25	Παραγωγα πυριδαζινονης
TR200102001T2 (tr)	2001-12-21	P38 kinaz inhibitörleri olarak sübstitüe edilmiş pirazoller
ATE346070T1 (de)	2006-12-15	Purinderivate als kinaseinhibitoren
ATE316527T1 (de)	2006-02-15	Substituierte indolinone als tyrosinkinase inhibitoren
DE60226469D1 (de)	2008-06-19	Biphenylkarbonsäureamidderivate als p38 kinase-inhibitoren
NI201000059A (es)	2010-09-13	Inhibidores de la cinasa c-fms.
ATE445613T1 (de)	2009-10-15	Indolylmaleimidderivative als proteinkinase-c- inhibitoren
UA93351C2 (uk)	2011-02-10	Похідні фталазіну як інгібітори parp
MX2009002229A (es)	2009-03-16	Benzotriazoles como moduladores de cinasas.
ATE286045T1 (de)	2005-01-15	Tyrosin kinaseinhibitoren
DK1317442T3 (da)	2006-02-13	Quinolinonderivater som tyrosinkinaseinhibitorer
SE0202465D0 (sv)	2002-08-14	New compounds
IS6524A (is)	2002-08-23	5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
AU2001288374A1 (en)	2002-03-22	Substituted oxindole derivatives as tyrosine kinase inhibitors
DE60211223D1 (de)	2006-06-08	Piperidinderivate als Kalium-Kanal Blockers
ITMI20021620A1 (it)	2004-01-23	Composto ad ativita' antitumorale
ATE355265T1 (de)	2006-03-15	Biphenylcarboxamidderivate und ihre verwendung als p38 kinase inhibitoren
BRPI0407841A (pt)	2006-11-14	inibidores heterocìclicos de quinase
BR0109542A (pt)	2003-06-10	Derivados de imidazopirina alquilados
SE0103710D0 (sv)	2001-11-07	Compounds
NO20022232D0 (no)	2002-05-10	Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
DE602004026905D1 (de)	2010-06-10	2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
ATE333457T1 (de)	2006-08-15	Zyklische gmp-spezifische phosphodiesteraseinhibitoren